Conclusion
Currently, there is no FDA approved pharmacologic therapy. Disease
management is based on prevention and quarantine. Pharmacologic therapy
choices are all off-label. Several antiviral components are also being
administered as off-label therapy. Oseltamivir, Hydroxychloroquine, and
Kaletra are currently being used. Monoclonal Antibodies can also be a
treatment choice but are restricted by viral mutations and peptide base
changes. Vitamins B, C, and D appear to be useful in enhancing the
immunity system of patients with deficiencies. Zinc and Selenium can
also be used for that purpose. Side effects and contraindications must
also be taken into account since higher mortality rates are reported in
patients with underlying disorders. The use of corticosteroids must be
limited to specific cases otherwise immunity system’s suppression could
lead to exacerbation of the disease. Depending on SARS-CoV and
SARS-CoV-2 high sequence homology, relevant data can be utilized in
choosing therapy. Antivirals seem to be the choice of therapy; along
with monoclonal antibodies. Clinical Trials and more studies need to be
conducted to determine efficacy and appropriate dosage and therapy
period.
Conflict of interest
The authors have no conflicts of interest relevant to this article.
Funding
This research did not receive any specific grant from funding agencies
in the public, commercial, or not-for-profit sectors.
References
1. Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and
Blood Safety. Transfusion Medicine Reviews. 2020.
2. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T,
Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and
Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020.
3. Xu YH, Dong JH, An WM, Lv XY, Yin XP, Zhang JZ, et al. Clinical and
computed tomographic imaging features of novel coronavirus pneumonia
caused by SARS-CoV-2. The Journal of infection. 2020.
4. Velavan TP, Meyer CG. The COVID-19 epidemic. Tropical Medicine and
International Health. 2020;25(3):278-80.
5. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019
(COVID-19): The epidemic and the challenges. International Journal of
Antimicrobial Agents. 2020.
6. Organization WH. Corona virus statistics. 2020.
7. Organization WH. Pandemic state.
8. Zhang L, Liu Y. Potential Interventions for Novel Coronavirus in
China: A Systemic Review. Journal of medical virology. 2020.
9. Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al.
Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut.
2020.
10. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical
findings in a group of patients infected with the 2019 novel coronavirus
(SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ
(Clinical research ed). 2020;368:m606.
11. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of
coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity. 2020.
12. Cao Q, Chen Y-C, Chen C-L, Chiu C-H. SARS-CoV-2 infection in
children: Transmission dynamics and clinical characteristics. Journal of
the Formosan Medical Association= Taiwan yi zhi. 2020.
13. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2
therapeutics. Drug development research. 2020.
14. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory
Responses: From Mechanisms to Potential Therapeutic Tools. Virologica
Sinica. 2020.
15. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological
findings of COVID-19 associated with acute respiratory distress
syndrome. The Lancet Respiratory Medicine. 2020.
16. Qiao J. What are the risks of COVID-19 infection in pregnant women?
The Lancet. 2020.
17. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al.
Epidemiologic Features and Clinical Course of Patients Infected With
SARS-CoV-2 in Singapore. Jama. 2020.
18. Song Y, Liu P, Shi XL, Chu YL, Zhang J, Xia J, et al. SARS-CoV-2
induced diarrhoea as onset symptom in patient with COVID-19. Gut. 2020.
19. Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, et al. Systematic
Comparison of Two Animal-to-Human Transmitted Human Coronaviruses:
SARS-CoV-2 and SARS-CoV. Viruses. 2020;12(2).
20. Huang WH, Teng LC, Yeh TK, Chen YJ, Lo WJ, Wu MJ, et al. 2019 novel
coronavirus disease (COVID-19) in Taiwan: Reports of two cases from
Wuhan, China. Journal of Microbiology, Immunology and Infection. 2020.
21. Gross A, Thiemig D, Koch FW, Schwarz M, Glaser S, Albrecht T. CT
appearance of severe, laboratory-proven coronavirus disease 2019
(COVID-19) in a Caucasian patient in Berlin, Germany. RoFo :
Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.
2020.
22. Sun D, Li H, Lu XX, Xiao H, Ren J, Zhang FR, et al. Clinical
features of severe pediatric patients with coronavirus disease 2019 in
Wuhan: a single center’s observational study. World journal of
pediatrics : WJP. 2020.
23. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical
Characteristics of 138 Hospitalized Patients With 2019 Novel
Coronavirus-Infected Pneumonia in Wuhan, China. Jama. 2020.
24. Liu KC, Xu P, Lv WF, Qiu XH, Yao JL, Gu JF, et al. CT manifestations
of coronavirus disease-2019: A retrospective analysis of 73 cases by
disease severity. European journal of radiology. 2020;126:108941.
25. Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of
pneumonia patients co-infected with 2019 novel coronavirus and influenza
virus in Wuhan, China. Journal of medical virology. 2020.
26. Cheng SC, Chang YC, Fan Chiang YL, Chien YC, Cheng M, Yang CH, et
al. First case of Coronavirus Disease 2019 (COVID-19) pneumonia in
Taiwan. Journal of the Formosan Medical Association. 2020.
27. Ma J, Xia P, Zhou Y, Liu Z, Zhou X, Wang J, et al. Potential effect
of blood purification therapy in reducing cytokine storm as a late
complication of severe COVID-19. Clinical immunology (Orlando, Fla).
2020:108408.
28. Katzung BG. Basic&Clinical pharmacology fourteenth Edition.
2018:833.
29. Jameson F, Kasper,Hauser,Longo,Loscalzo. Harrison’s Principle of
Internal Medicine 20th Edition. 2018:913.
30. Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against
coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine.
International Journal of Antimicrobial Agents. 2020:105945.
31. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro
Antiviral Activity and Projection of Optimized Dosing Design of
Hydroxychloroquine for the Treatment of Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2). Clinical infectious diseases : an
official publication of the Infectious Diseases Society of America.
2020.
32. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown
apparent efficacy in treatment of COVID-19 associated pneumonia in
clinical studies. Bioscience trends. 2020.
33. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results
of an open-label non-randomized clinical trial. Int J Antimicrob Agents.
2020:105949.
34. Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A Systematic Review of
Lopinavir Therapy for SARS Coronavirus and MERS Coronavirus-A Possible
Reference for Coronavirus Disease-19 Treatment Option. Journal of
medical virology. 2020.
35. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined
with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A
retrospective cohort study. The Journal of infection. 2020.
36. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the
index patient who caused tertiary transmission of coronavirus disease
2019 in Korea: The application of lopinavir/ritonavir for the treatment
of COVID-19 pneumonia monitored by quantitative RT-PCR. Journal of
Korean Medical Science. 2020;35(6).
37. Post TW. Kaletra: UptoDate in Waltham,MA; 2020, 7 April.
38. Database D. Remdesivir 2020,April 14 [Available from:
https://www.drugbank.ca/drugs/DB14761.
39. Kruse RL. Therapeutic strategies in an outbreak scenario to treat
the novel coronavirus originating in Wuhan, China. F1000Research.
2020;9:72.
40. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease
2019 (COVID-19). Drug discoveries & therapeutics. 2020;14(1):58-60.
41. Lu H. Drug treatment options for the 2019-new coronavirus
(2019-nCoV). Biosci Trends. 2020;14(1):69-71.
42. Columbus C, Brust KB, Arroliga AC. 2019 novel coronavirus: an
emerging global threat. Baylor University Medical Center Proceedings.
2020.
43. Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about
clinical trials for 2019-nCoV infection. Clinical pharmacology and
therapeutics. 2020.
44. DrugBank Database. Favipiravir 2020, 7 April [Available from:
https://www.drugbank.ca/drugs/DB12466.
45. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro
from COVID-19 virus and discovery of its inhibitors. bioRxiv. 2020.
46. Junmei W. Fast Identification of Possible Drug Treatment of
Coronavirus Disease -19 (COVID-19) Through Computational Drug
Repurposing Study2020.
47. Ted W. Post. Indinavir2020,April 11.
48. Chang Y-C, Tung Y-A, Lee K-H, Chen T-F, Hsiao Y-C, Chang H-C, et al.
Potential therapeutic agents for COVID-19 based on the analysis of
protease and RNA polymerase docking. 2020.
49. Chen H, Zhang Z, Wang L, Huang Z, Gong F, Li X, et al. First
Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive
and Experienced COVID-19 Patients. medRxiv. 2020:2020.03.22.20034041.
50. Chen YW, Yiu C-PB, Wong K-Y. Prediction of the SARS-CoV-2
(2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening
reveals velpatasvir, ledipasvir, and other drug repurposing candidates.
F1000Research. 2020;9:129-.
51. Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J, et al. α-Ketoamides
as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication:
Structure-Based Design, Synthesis, and Activity Assessment. Journal of
medicinal chemistry. 2020:acs.jmedchem.9b01828.
52. Baumann CA, Badamchian M, Goldstein AL. Thymosin α1 antagonizes
dexamethasone and CD3-induced apoptosis of CD4+CD8+ thymocytes through
the activation of cAMP and protein kinase C dependent second messenger
pathways1This work is supported, in part, by a grant from SciClone
Pharmaceuticals, San Mateo, California, to M. Badamchian and a
pre-doctoral fellowship from the Philip Morris Companies Inc. to C.A.
Baumann.1. Mechanisms of Ageing and Development. 1997;94(1):85-101.
53. M I Joffe NRS, and A R Rabson. Lymphocyte subsets in measles.
Depressed helper/inducer subpopulation reversed by in vitro treatment
with levamisole and ascorbic acid. J Clin Invest. 1983;72(3):971–80.
54. Hemilä H. Vitamin C and SARS coronavirus. The Journal of
antimicrobial chemotherapy. 2004;52:1049-50.
55. Nonnecke BJ, McGill JL, Ridpath JF, Sacco RE, Lippolis JD, Reinhardt
TA. Acute phase response elicited by experimental bovine diarrhea virus
(BVDV) infection is associated with decreased vitamin D and E status of
vitamin-replete preruminant calves1. Journal of Dairy Science.
2014;97(9):5566-79.
56. Guillin OM, Vindry C, Ohlmann T, Chavatte L. Selenium,
Selenoproteins and Viral Infection. Nutrients. 2019;11(9):2101.
57. Database D. Ebselen 2020,March 1 [Available from:
https://www.drugbank.ca/drugs/DB12610.
58. Post TW. Bictegravir: UpToDate; 2020, April 12.
59. Database D. Bictegravir 2020,March 1 [Available from:
https://www.drugbank.ca/drugs/DB11799.
60. Villalaín J. Membranotropic effects of arbidol, a broad anti-viral
molecule, on phospholipid model membranes. The journal of physical
chemistry B. 2010;114(25):8544-54.
61. Liu Q, Xiong H-r, Lu L, Liu Y-y, Luo F, Hou W, et al. Antiviral and
anti-inflammatory activity of arbidol hydrochloride in influenza A
(H1N1) virus infection. Acta Pharmacologica Sinica. 2013;34(8):1075-83.
62. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases
with Coronavirus Disease 2019 in Wuhan, China. Clinical infectious
diseases : an official publication of the Infectious Diseases Society of
America. 2020.
63. Alex Z, Vladimir A, Alexander Z, Bogdan Z, Victor T, Dmitry S. B, et
al. Potential COVID-2019 3C-like Protease Inhibitors Designed Using
Generative Deep Learning Approaches2020.
64. Database D. Prulifloxacin 2020,March 1 [Available from:
https://www.drugbank.ca/drugs/DB11892.
65. Katzung BG. Basic&Clinical pharmacology fourteenth Edition2018
April 9th 2020. 833 p.
66. Database D. Tideglusib 2020,March 1 [Available from:
https://www.drugbank.ca/drugs/DB12129.
67. Database d. PX-12 2020,March 1 [Available from:
https://www.drugbank.ca/drugs/DB05448.
68. CaymanChem. TDZD-8 2020,April 12 [Available from:
https://www.caymanchem.com/product/16287/tdzd-8.
69. Medscape. Parasite Drug Shows Early Promise Against COVID-19 in
Vitro 2020,April 8 [Available from:
https://www.medscape.com/viewarticle/928345.
70. Database D. Bepotastine. 2020,April 11.
71. Medical Press. Many drugs already approved by FDA may have promise
against COVID-19 2020,March 24 [Available from:
https://medicalxpress.com/news/2020-03-drugs-fda-covid-.html.
72. Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. Management of corona
virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang da xue
xue bao Yi xue ban = Journal of Zhejiang University Medical sciences.
2020;49(1):0.
73. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical Features of
85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational
Study. American Journal of Respiratory and Critical Care
Medicine.0(ja):null.
74. Zhang H, Huang Y, Xie C. The Treatment and Outcome of a Lung Cancer
Patient Infected with SARS-CoV-2. Journal of thoracic oncology :
official publication of the International Association for the Study of
Lung Cancer. 2020.
75. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential
therapy for COVID-19. The Lancet Infectious diseases. 2020.
76. Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment
with convalescent plasma for critically ill patients with SARS-CoV-2
infection. Chest. 2020.
77. Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel
treatment approach to the novel coronavirus: an argument for the use of
therapeutic plasma exchange for fulminant COVID-19. Critical Care.
2020;24(1):128.